Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZP4207 vs glucagon in hypoglycemic type 1 diabetes
2015-005287-41Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dasiglucagon in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Zealand Pharma. Primary endpoints: Pharmacodynamic endpoint and Pharmacokinetic endpoints. Started Dec 2015; status: completed.
02
Drugs
dasiglucagon
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2015-005287-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005287-41.